Kiwi Tigress
01:58

Great article, would you like to share it?

@Barcode：$Hims & Hers Health Inc.(HIMS)$ $Novo-Nordisk A/S(NVO)$ $Eli Lilly(LLY)$ 💊📉🔥 $HIMS Just Lost Its Highest-Margin Growth Engine 🔥📉💊 $HIMS is getting punished after its GLP-1 cash cow hit a wall. The company’s pivot away from compounded Wegovy copycats toward branded $NVO and $LLY therapies just detonated profitability, crushed margins, and exposed how dependent the growth story had become on one exceptionally lucrative category. The market reaction says it all. 🔴 EPS: -$0.40 vs Est. $0.03 🔴 Revenue: $608.1M vs Est. $616.9M 🔴 First quarterly loss in 3 years 🔴 Gross Margin: 65% vs 73% YoY 🔴 U.S. Revenue: -8% YoY 🔴 Stock slammed double digits post earnings I’m watching a company transition from a high-margin disruptor into a much lower-margin pharmaceutical distributor model almost overnight. Management is still projecting confidence: “We expect growth to accelerate from here, and have high conviction in our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.” But the numbers underneath the surface tell a far more complicated story. $HIMS Q1 2026 earnings revealed a business trying to reinvent itself while simultaneously absorbing margin compression, restructuring charges, legal settlements, acquisition integration costs, and weakening domestic momentum. The result was brutal. Net income swung violently from a $49.5M profit last year to a $92.1M loss. A $33.5M restructuring charge tied to the GLP-1 pivot, combined with a $15M legal settlement and collapsing margins, completely overwhelmed what management hoped would be viewed as a strategic transition quarter. At the same time, the company’s once unstoppable U.S. engine suddenly reversed. That matters enormously. For most of 2025, investors rewarded $HIMS because it looked like a scalable, high-margin digital healthcare platform with accelerating subscriber economics. Q1 shattered that narrative. Instead, international expansion became the only thing preventing a near outright revenue stagnation headline. 🌍 International revenue surged 969% YoY to $78.2M thanks to acquisitions including Zava and Livewell, while the pending Eucalyptus acquisition expands the company deeper into Australia 🇦🇺 and Japan 🇯🇵. Without that international contribution, this quarter would have looked dramatically worse. 🐂 Bull Case 🌍 International Scale Is Becoming Real Rest-of-world revenue exploded 969% YoY to $78.2M, validating management’s aggressive acquisition strategy and proving the platform can scale outside the United States. 📈 Strong Q2 Rebound Guidance Management guided Q2 revenue to $680M-$700M, implying roughly 26% YoY growth and suggesting Q1 may represent a temporary trough during the GLP-1 transition. 🧬 Expansion Into New Verticals The company continues expanding into testosterone, menopause, longevity, and personalised treatment categories. If successful, this diversifies revenue away from dependence on weight-loss medications. 💰 Long-Term TAM Still Massive Digital healthcare remains structurally underpenetrated globally. If $HIMS successfully integrates international operations while maintaining subscriber growth, the long-term platform opportunity remains substantial. 🐻 Bear Case 🇺🇸 The U.S. Engine Is Breaking U.S. revenue fell 8% YoY to $529.9M. This is a dramatic reversal from the hypergrowth trajectory investors became accustomed to throughout 2025. If domestic growth has structurally peaked, international acquisitions may simply be masking deterioration in the core business. 📉 Margin Compression Is Severe Gross margin collapsed from 73% to 65% as the business pivoted toward branded GLP-1 distribution. That fundamentally changes the economics of the company. Compounded GLP-1s were extraordinarily profitable. Branded pharma distribution is not. 🧾 Accounts Receivable Explosion Raises Questions Accounts receivable exploded from $32.1M to $149.6M in just one quarter. That is a staggering $117M cash absorption swing in a business model where customers typically pay upfront. I’m watching this metric very closely because subscription businesses generally should not exhibit this kind of receivables behaviour unless something material changed operationally. ⚠️ Earnings Quality Deteriorated Sharply Free cash flow stayed positive largely because the company delayed payments to suppliers, with accounts payable jumping over $160M sequentially. That working capital strategy can support short-term optics, but it is not a sustainable long-term solution. ⚖️ Verdict: 🔴 Bearish Near Term I believe the market is correctly reassessing the quality of the $HIMS growth story. Management continues framing this as a strategic evolution toward a larger global healthcare ecosystem, but the near-term reality is much uglier: • Domestic revenue is shrinking • Margins are collapsing • Monetisation is weakening • Receivables exploded • Operating leverage deteriorated • Legal and restructuring costs are piling up International expansion is impressive, but it currently looks more like a buffer against domestic weakness than proof of a stronger business model. The key question now becomes whether Q1 was a temporary dislocation tied to the GLP-1 pivot, or the beginning of a structurally lower-margin growth era. If Q2 fails to show meaningful domestic reacceleration, the market may start valuing $HIMS far differently than it did during the compounded GLP-1 boom. 𝐊𝐞𝐲 𝐓𝐡𝐞𝐦𝐞𝐬 🔴🔴 U.S. Revenue Engine Throws a Rod For the first time, U.S. revenue contracted, falling 8% YoY from $578.7M to $529.9M. That completely breaks the hypergrowth narrative investors previously rewarded. The entire quarter’s consolidated growth was effectively manufactured by the 969% international surge. 🔴 GLP-1 Strategic Pivot Crushed Margins The transition away from compounded GLP-1s toward branded therapies immediately detonated profitability. Gross margin fell 800 basis points YoY, while restructuring costs tied to inventory write-downs added another $33.5M hit. The business model now appears structurally lower margin. 🔴 Massive Spike in Accounts Receivable Accounts receivable surged from $32M to nearly $150M in one quarter. That is one of the most important numbers in the entire report. In a direct-to-consumer subscription platform, investors should demand detailed explanations for a receivables increase of this magnitude. 🟢 International Expansion Is Scaling Fast International revenue is now approaching 13% of total sales. The Zava and Livewell integrations appear successful so far, while the Eucalyptus acquisition could materially accelerate international exposure further. ⚪ Subscriber Growth Continues But Monetisation Softens Subscribers rose 9% YoY to 2.58M. However, monthly revenue per subscriber fell from $85 to $80, reflecting weaker monetisation dynamics and lower-margin international mix. 📊 Guidance Snapshot 📈 Q2 Revenue: $680M-$700M Implies roughly 26% YoY growth and 13% sequential acceleration. 📉 Q2 Adjusted EBITDA: $35M-$55M Margin profile remains far below historical peak levels. 📈 FY2026 Revenue: $2.8B-$3.0B Strong top-line growth still expected despite GLP-1 transition disruption. 📉 FY2026 Adjusted EBITDA: $275M-$350M Confirms the company has exited its margin expansion era and entered a prolonged investment-heavy phase. ❓Key Questions Going Forward • Was the U.S. contraction entirely GLP-1 related, or are legacy categories weakening too? • Is 65% now the structural gross margin ceiling? • Why did receivables explode by $117M in a subscription business? • Are legal and restructuring costs truly contained to Q1? • Can international expansion offset weakening domestic economics long term? I’m seeing a company still capable of strong top-line growth, but the quality of that growth just deteriorated materially. And markets eventually care more about quality than headlines. 📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀 Trade like a boss! Happy trading ahead, Cheers, BC 📈
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment